Acadian Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Acadian Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-802	Closed	-$3K	–	2275
2026 Q1	$3K	Buy	+802	New	+$3K	﹤0.01%	1992
2024 Q1	–	Sell	-6,054	Closed	-$152K	–	1817
2023 Q4	$152K	Buy	+6,054	New	+$147K	﹤0.01%	1284
2022 Q1	–	Sell	-1,909	Closed	-$130K	–	1832
2021 Q4	$130K	Buy	+1,909	New	+$241K	﹤0.01%	1328
2020 Q2	–	Sell	-68	Closed	-$20K	–	2359
2020 Q1	$20K	Buy	+68	New	+$19.3K	﹤0.01%	1649
2018 Q4	–	Sell	-277	Closed	-$81K	–	1852
2018 Q3	$81K	Buy	+277	New	+$117K	﹤0.01%	1259

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management's XFOR Position: Q2 2026 in Review

Acadian Asset Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 802 shares — an estimated $3K sold.

Acadian Asset Management first reported a position in XFOR in Q3 2018 and held it in 5 quarters. The position peaked at $152K in Q4 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Acadian Asset Management reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Acadian Asset Management sold 802 X4 Pharmaceuticals shares in Q2 2026, an estimated $3K.
Acadian Asset Management first reported a position in X4 Pharmaceuticals in Q3 2018 and held it in 5 quarters.
Acadian Asset Management's X4 Pharmaceuticals position peaked at $152K in Q4 2023.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.